Auspex Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people with movement disorders and other rare diseases, including orphan diseases. Its pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea (abnormal involuntary movements) associated with Huntington's disease, an orphan disease, tardive dyskinesia and Tourette syndrome in the pediatric population, which is an orphan disease, as well as other orphan indications. Its lead product candidate is SD-809, which is a small molecule inhibitor of vesicular monoamine transporter 2 (VMAT2). Its other programs include SD-560, SD-1077 and SD-254.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:ASPX
CUSIPN/A
WebN/A
Phone+1-858-5582400
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-61.66%
Return on Assets-50.55%
Miscellaneous
EmployeesN/A
Outstanding Shares31,820,000
Market Cap$3,210.00
Auspex Pharmaceuticals (NASDAQ:ASPX) Frequently Asked Questions
What is Auspex Pharmaceuticals' stock symbol?
Auspex Pharmaceuticals trades on the NASDAQ under the ticker symbol "ASPX."
How were Auspex Pharmaceuticals' earnings last quarter?
Auspex Pharmaceuticals Inc (NASDAQ:ASPX) posted its quarterly earnings results on Monday, March, 16th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.59) by $0.15. View Auspex Pharmaceuticals' Earnings History.
What is the consensus analysts' recommendation for Auspex Pharmaceuticals?
0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Auspex Pharmaceuticals in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."
Has Auspex Pharmaceuticals been receiving favorable news coverage?
Headlines about ASPX stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Auspex Pharmaceuticals earned a coverage optimism score of 0.15 on Accern's scale. They also gave news headlines about the biopharmaceutical company an impact score of 45.89 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.
How do I buy shares of Auspex Pharmaceuticals?
Shares of ASPX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Auspex Pharmaceuticals' stock price today?
One share of ASPX stock can currently be purchased for approximately $100.96.
How big of a company is Auspex Pharmaceuticals?
Auspex Pharmaceuticals has a market capitalization of $3.21 billion.
How can I contact Auspex Pharmaceuticals?
Auspex Pharmaceuticals' mailing address is 3333 N Torrey Pines Ct Ste 400, LA JOLLA, CA 92037-1023, United States. The biopharmaceutical company can be reached via phone at +1-858-5582400.
MarketBeat Community Rating for Auspex Pharmaceuticals (NASDAQ ASPX)
MarketBeat's community ratings are surveys of what our community members think about Auspex Pharmaceuticals and other stocks. Vote "Outperform" if you believe ASPX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASPX will underperform the S&P 500 over the long term. You may vote once every thirty days.
